Navigation Links
inVentiv Health Selected to Provide Sales Operations Support for Santarus
Date:11/14/2011

leverage we may incur in connection with the financing thereof, on the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sa
'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AWAC Becomes inVentiv Medical Management™
2. Ocean Tomo Study Ranks Top 25 Most Inventive Companies for Bloomberg BusinessWeek
3. Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
4. iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers
5. inVentiv Health to Announce First Quarter 2009 Results and Conduct Conference Call on Friday, May 8
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. "Tomorrows Health" TV Series Showing the Life Science Industrys Quest to Save and Improve Lives, to Air on Select NBC Stations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... BOSTON, March 17 Alimera Sciences,and pSivida Ltd ... today announced that,they have amended their license and ... III investigative treatment for,diabetic macular edema (DME), and ... the future profits of Medidur FA from 50 ...
... Contract from Anhui ... Huayuan Pharmaceutical Co., Ltd., ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of modernized ... that the Company has been granted SFDA,approval and is ...
... March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: VIOND ) ... of 2007., The Company reported a net loss ... ended December 31, 2007, compared with a net loss ... common shares,outstanding for the years ended December 31, 2007 ...
Cached Biology Technology:Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4
(Date:7/9/2014)... which animals can be found, concern mounts over the ... range for a host mean new territory for its ... of UC Santa Barbara scientists, including parasitologists Ryan Hechinger ... Journal of Biogeography , Hechinger, Kuris and colleagues ... Hosts may actually lose their parasites when the hosts ...
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... women may worry about the effects of air pollution on ... carbon monoxide and fine particles in the air during pregnancy ... or preeclampsia -- a serious condition that arises only during ... a University at Buffalo epidemiologist. , The research was ...
... Safran, a professor at the Weizmann Institute in Israel, has ... Pierre-Gilles De Gennes Lecture Prize. The prize, accompanied by 1,000, ... (EPJE). Safran is the author of numerous articles in ... Prize, which was named after the Nobel laureate who founded ...
... cessation therapy is quickly taking shape. New evidence ... on Drug Abuse (NIDA) suggests that combining information about ... habits can accurately predict which nicotine replacement therapy will ... conceivable we,ll have a practical test that could take ...
Cached Biology News:Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Personalized approach to smoking cessation may be reality in 3-5 years 2Personalized approach to smoking cessation may be reality in 3-5 years 3
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... whose sequence is from rat SCAMP 5. The sequence of ... - Q - P - Q - T - Q - ... - Y - T - Y - S - N(233). ... with the polyclonal antibody that reacts with this product and the ...
Biology Products: